PRECISION BIOSCIENCES INC 8-K

What Happened

• Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on May 5, 2026 (Item 2.02) to announce its financial results for the quarter ended March 31, 2026 (Q1 2026).
• The company furnished a press release as Exhibit 99.1 to the 8-K; that press release contains the full financial results and is incorporated by reference into the filing. The Form 8-K was signed by Chief Financial Officer John Alexander Kelly.

Key Details

• Filing date: May 5, 2026.
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K signed by CFO John Alexander Kelly.

Why It Matters

• This filing notifies investors that Precision BioSciences has publicly released its quarterly earnings/financial results; the press release will contain the company’s reported revenue, expenses, net loss/profit, cash position and any management commentary or guidance.
• Retail investors should read the Exhibit 99.1 press release to see the actual financial metrics and any forward-looking statements that could affect the stock (earnings, revenue trends, cash runway, pipeline progress). This 8-K itself is the formal disclosure that those results are now public.